Astrazeneca (AZN) Payables (2009 - 2026)
Astrazeneca (AZN) posted quarterly Payables of $22.9 billion for Q2 2026, down 4.66% year-over-year from $24.0 billion in Q2 2025, and up 199.1% quarter-over-quarter from -$23.1 billion in Q1 2026.
Astrazeneca (AZN) Payables (2009 - 2026) Analysis & Trends
Astrazeneca's Payables history runs 18 years deep, the most recent figure standing at $22.9 billion for Q2 2026.
- In Q2 2026, Payables fell 4.66% year-over-year to $22.9 billion; the TTM figure through Jun 2026 stood at $22.9 billion (down 4.66% YoY), while the FY2025 annual figure was $24.6 billion, up 11.3% from the prior year.
- Payables for Q2 2026 stood at $22.9 billion, up from -$23.1 billion in the prior quarter.
- The five-year high for Payables was $24.6 billion in Q4 2025, with the low at -$25.6 billion in Q3 2025.
- The 5-year median for Payables is -$19.1 billion (2022), against an average of -$6.4 billion.
- The sharpest annual moves came in 2022 and 2025: Payables sank 31.63% in 2022, then surged 218.73% in 2025.
- Astrazeneca's Payables stood at $18.7 billion in 2022, then rose by 16.96% to $21.9 billion in 2023, then grew by 1.26% to $22.1 billion in 2024, then gained by 11.3% to $24.6 billion in 2025, then fell by 7.08% to $22.9 billion in 2026.
- Business Quant data shows AZN's Payables at $22.9 billion in Q2 2026, -$23.1 billion in Q1 2026, and $24.6 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 20.92 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 33.30 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 5.96 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 4.26 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 22.89 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 2.87 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 674.00 Mn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 7.03 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -25.00 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 8.31 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.89 Bn |
| Mar 31, 2026 | -23.10 Bn |
| Dec 31, 2025 | 24.64 Bn |
| Sep 30, 2025 | -25.65 Bn |
| Jun 30, 2025 | 24.01 Bn |
| Mar 31, 2025 | -22.99 Bn |
| Dec 31, 2024 | 22.14 Bn |
| Sep 30, 2024 | -22.45 Bn |
| Jun 30, 2024 | -20.22 Bn |
| Mar 31, 2024 | -20.18 Bn |
| Dec 31, 2023 | 21.86 Bn |
| Sep 30, 2023 | -21.06 Bn |
| Jun 30, 2023 | -19.55 Bn |
| Mar 31, 2023 | -19.80 Bn |
| Dec 31, 2022 | 18.69 Bn |
| Sep 30, 2022 | -18.44 Bn |
| Jun 30, 2022 | -17.48 Bn |
| Mar 31, 2022 | -18.67 Bn |
| Dec 31, 2021 | 18.55 Bn |
| Sep 30, 2021 | -19.27 Bn |